Evaluating Cognitive Effects and Anti-Inflammatory Mechanisms of Deep Brain Stimulation in the Nucleus Basalis of Meynert for Alzheimer’s Disease

Category	Detail
Condition	Alzheimer’s disease (moderate-to-severe stages)
Key Mechanisms	Deep brain stimulation of the nucleus basalis of Meynert (NBM-DBS) modulates cholinergic pathways and systemic inflammatory markers
Target Population	Patients with moderate-to-severe Alzheimer’s disease
Care Setting	Specialized neurosurgical and neuropsychiatric clinical centers capable of stereotactic DBS implantation and longitudinal cognitive assessment

NBM-DBS stabilized cognitive performance in patients with moderate AD over 12 months, as measured by MoCA and BNT.
Patients with severe AD showed continued cognitive decline despite NBM-DBS treatment.
NBM-DBS was associated with increased anti-inflammatory cytokines (IL-10, IL-27) and decreased pro-inflammatory chemokines (CXCL10, RANTES) at 12 months.

Confirm probable AD diagnosis using NINCDS-ADRDA criteria.
Assess dementia severity with Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE).
Exclude mild AD (MMSE > 20) and contraindications for surgery.

Consider bilateral NBM-DBS implantation in moderate-to-severe AD patients after multidisciplinary evaluation.
Use stereotactic surgery with MRI guidance to target the posterior Ch4p subregion of the NBM.
Program stimulation parameters at approximately 20 Hz, 2.0–3.0 V, 90-μs pulse width starting one month post-surgery.

Perform serial neuropsychiatric assessments including MoCA, BNT, MMSE, ADAS-Cog, and behavioral scales at baseline and multiple intervals up to 12 months.
Monitor serum cytokine and chemokine profiles preoperatively and at 12 months to evaluate immunomodulatory effects.
Conduct postoperative imaging to confirm electrode placement and exclude complications.

Potential risks include surgical complications; however, no severe or persistent stimulation-related adverse events were reported in this study.
Careful patient selection is critical to optimize benefit and minimize risks.

Nine patients aged 59–80 years with moderate-to-severe AD (MMSE 2–16), stratified by disease severity (CDR 2 or 3).

NBM-DBS may stabilize cognition in moderate AD but is less effective in severe AD; immunomodulatory effects suggest a potential mechanism of action.

Select patients with moderate AD (CDR = 2) for NBM-DBS to maximize cognitive stabilization potential.
Use comprehensive neuropsychiatric batteries to monitor cognitive and behavioral changes longitudinally.
Incorporate serum cytokine profiling to assess systemic inflammatory response to DBS therapy.
Ensure multidisciplinary team involvement including neurology, neurosurgery, neuropsychology, and immunology for optimal care.
Confirm electrode placement with postoperative imaging to ensure accurate targeting.

Clinical Scorecard: Evaluating Cognitive Effects and Anti-Inflammatory Mechanisms of Deep Brain Stimulation in the Nucleus Basalis of Meynert for Alzheimer’s Disease